AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

California Resources Corp

$55.79 +$9.40 (+20.26%)
NYSE · 14 Sep 2026 20:00 UTC
Previous Close
$56.75
Day Range
$55.59$57.69
Year Range
$43.24$71.98
Market Cap
4.95B
AVG Volume
843.21K
Trailing/Forward PE
-41.95/13.35
PEG ratio
44.8
Dividend Yield
2.90%
Next Earnings Date
2026-11-03
Primary Exchange
New York Stock ExchangeUS
Revenue (USD)
01B2B3B4B2016201720182019202020212022202320242025
CRC Revenue (USD) by year
PeriodRevenue (USD)
20253.48B
20242.96B
20232.81B
20223.26B
20212.56B
20201.61B
20192.69B
20183.06B
20172.1B
20161.75B
Net Income (USD)
-1B01B2B2016201720182019202020212022202320242025
CRC Net Income (USD) by year
PeriodNet Income (USD)
2025363M
2024376M
2023564M
2022524M
2021612M
20201.74B
2019-29M
2018319M
2017-267M
2016279M
Operating Income (USD)
-500M0500M1B1.5B2016201720182019202020212022202320242025
CRC Operating Income (USD) by year
PeriodOperating Income (USD)
2025724M
2024649M
2023894M
20221.35B
2021928M
202090M
2019851M
20181.17B
201773M
2016-37M
EBITDA (USD)
01B2B3B2016201720182019202020212022202320242025
CRC EBITDA (USD) by year
PeriodEBITDA (USD)
20251.23B
20241.08B
20231.07B
20221.05B
2021520M
20202.45B
2019961M
20181.33B
2017626M
20161.08B
Cash Flows (USD)
-400M-200M0200M400M600M2016201720182019202020212022202320242025
CRC Cash Flows (USD) by year
PeriodCash Flows (USD)
2025543M
2024350M
2023460M
2022311M
2021466M
202059M
2019221M
2018-229M
2017-123M
201644M
EPS (USD)
-10-505102016201720182019202020212022202320242025
CRC EPS (USD) by year
PeriodEPS (USD)
20254.08
20244.11
20237.72
20226.87
20217.49
20206.39
2019-0.59
20186.57
2017-6.14
20166.28
Expenses (USD)
0250M500M750M1BSG&ACapex2016201720182019202020212022202320242025
CRC Expenses (USD) by year
PeriodExpenses (USD)
2025893M
2024576M
2023452M
2022601M
2021394M
2020299M
2019745M
2018989M
2017639M
2016343M
Cash & Debt (USD)
02B4B6BCashLong Term DebtShort Term Debt2016201720182019202020212022202320242025
CRC Cash & Debt (USD) by year
PeriodCash & Debt (USD)
2025132M
2024372M
2023496M
2022307M
2021305M
202028M
201917M
201817M
201720M
201612M
Debt ratios
00.511.520182019202020212022202320242025
CRC Debt ratios by year
PeriodDebt ratios
20250.28
20240.23
20230.02
20220.07
20210.06
20200.11
20191.26
20181.38
Margins
0%20%40%60%2016201720182019202020212022202320242025
CRC Margins by year
PeriodMargins
202537.4%
202440.58%
202347.14%
202253.35%
202149.63%
202030.21%
201948.2%
201852.73%
201731.2%
201629.61%
Return on Capital
-100%-50%0%50%100%150%2016201720182019202020212022202320242025
CRC Return on Capital by year
PeriodReturn on Capital
20259.88%
202410.63%
202325.42%
202228.11%
202136.26%
2020147.55%
2019-5.73%
201862.67%
201737.08%
2016-50.09%
Shares Outstanding
025M50M75M100M2016201720182019202020212022202320242025
CRC Shares Outstanding by year
PeriodShares Outstanding
202587M
202490.8M
202369.3M
202272.7M
202180.1M
202083.32M
201949.1M
201848.6M
201742.5M
201642.1M
Dividends (USD)
00.511.52202120222023202420252026
CRC Dividends (USD) by year
PeriodDividends (USD)
20261.22
20251.57
20241.4
20231.16
20220.79
20210.17
Employee Count
01K2K3K2016201720182019202020212022202320242025
CRC Employee Count by year
PeriodEmployee Count
20252.5K
20241.55K
2023970
20221.06K
2021970
20201K
20191.25K
20181.5K
20171.45K
20162K
Book Value Per Share (USD)
-2002040602016201720182019202020212022202320242025
CRC Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
202542.23
202438.96
202332.02
202225.64
202121.07
202014.19
201910.31
201810.47
2017-16.94
2016-13.23
Total Assets (USD)
02B4B6B8B2016201720182019202020212022202320242025
CRC Total Assets (USD) by year
PeriodTotal Assets (USD)
20257.4B
20247.13B
20234B
20223.97B
20213.85B
20203.07B
20196.96B
20187.16B
20176.21B
20166.35B
PE Ratio
510152025med 10Aug 24Nov 24Mar 25Jun 25Oct 25Jan 26May 26
CRC PE Ratio by year
PeriodPE Ratio
May 2616.39
Apr 2615.52
Apr 2615.04
Apr 2615.95
Apr 2616.23
Mar 2616.51
Mar 2615.23
Mar 2614.73
Mar 2615.52
Feb 2612.9
Feb 2612.99
Feb 2612.48
Feb 2612.15
Jan 2611.73
Jan 2610.76
Jan 2610.51
Jan 269.99
Jan 2610.17
Dec 259.66
Dec 259.56
Dec 2510.6
Dec 2510.45
Nov 2510.48
Nov 2510.14
Nov 2510.71
Nov 2510.12
Oct 256.31
Oct 256.37
Oct 256.33
Oct 256.52
Oct 257.07
Sep 257.55
Sep 257.36
Sep 257.09
Sep 256.56
Aug 256.65
Aug 256.68
Aug 256.45
Aug 256.36
Aug 258.47
Jul 258.94
Jul 259.27
Jul 258.65
Jul 258.53
Jun 258.26
Jun 258.43
Jun 258.55
Jun 258.07
May 257.99
May 257.61
May 257.7
May 257.34
May 258.75
Apr 258.6
Apr 258.62
Apr 258.29
Apr 258.41
Mar 2510.58
Mar 2510.57
Mar 2510.53
Mar 2510.02
Feb 257.51
Feb 257.97
Feb 258.12
Feb 257.9
Jan 258.28
Jan 258.84
Jan 259.03
Jan 258.88
Jan 258.74
Dec 248.46
Dec 248.51
Dec 249.25
Dec 249.02
Nov 249.96
Nov 2410.03
Nov 249.52
Nov 249.58
Nov 2421.56
Oct 2421.78
Oct 2421.29
Oct 2422.29
Oct 2422.53
Sep 2421.37
Sep 2421.95
Sep 2420.73
Sep 2419.99
Aug 2421.79
Aug 2421.53
Aug 2420.88
Aug 2419.59
Aug 2412.93
Jul 2413.94
Jul 2414.15
Jul 2414.02
Jul 2414
Jun 2414.51
Jun 2413.27
Jun 2413.29
Jun 2412.95
Free Cash Flow Yield
5%7.5%10%12.5%15%med 9.82%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
CRC Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 267.97%
Sep 267.84%
Sep 268.2%
Aug 268.52%
Aug 268.35%
Aug 268.34%
Aug 268.44%
Jul 268.36%
Jul 268.22%
Jul 268.32%
Jul 268.38%
Jul 268.58%
Jun 268.19%
Jun 267.95%
Jun 267.5%
Jun 267.54%
May 267.42%
May 267.09%
May 267.19%
May 267.46%
May 269.13%
Apr 269.64%
Apr 269.95%
Apr 269.38%
Apr 269.22%
Mar 269.06%
Mar 269.82%
Mar 2610.15%
Mar 269.64%
Feb 2611%
Feb 2610.93%
Feb 2611.37%
Feb 2611.68%
Jan 2612.1%
Jan 2613.19%
Jan 2613.5%
Jan 2614.21%
Jan 2613.95%
Dec 2514.69%
Dec 2514.84%
Dec 2513.39%
Dec 2513.58%
Nov 2513.55%
Nov 2513.99%
Nov 2513.25%
Nov 2514.02%
Oct 2511.89%
Oct 2511.79%
Oct 2511.86%
Oct 2511.5%
Oct 2510.61%
Sep 259.93%
Sep 2510.19%
Sep 2510.58%
Sep 2511.44%
Aug 2511.29%
Aug 2511.23%
Aug 2511.63%
Aug 2511.79%
Aug 2510.75%
Jul 2510.19%
Jul 259.82%
Jul 2510.52%
Jul 2510.67%
Jun 2511.02%
Jun 2510.8%
Jun 2510.65%
Jun 2511.27%
May 2511.39%
May 2511.96%
May 2511.81%
May 2512.4%
May 2510.64%
Apr 2510.82%
Apr 2510.8%
Apr 2511.23%
Apr 2511.07%
Mar 258.79%
Mar 258.81%
Mar 258.84%
Mar 259.29%
Feb 257.24%
Feb 256.83%
Feb 256.7%
Feb 256.89%
Jan 256.57%
Jan 256.16%
Jan 256.03%
Jan 256.13%
Jan 256.22%
Dec 246.44%
Dec 246.39%
Dec 245.89%
Dec 246.03%
Nov 245.46%
Nov 245.42%
Nov 245.71%
Nov 245.68%
Nov 246.19%
Oct 246.13%
Price to Sales
11.251.51.7522.25med 1.32Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
CRC Price to Sales by year
PeriodPrice to Sales
Sep 261.23
Sep 261.26
Sep 261.2
Aug 261.16
Aug 261.18
Aug 261.18
Aug 261.31
Jul 261.32
Jul 261.34
Jul 261.32
Jul 261.32
Jul 261.29
Jun 261.35
Jun 261.39
Jun 261.47
Jun 261.46
May 261.49
May 261.56
May 261.53
May 261.48
May 261.71
Apr 261.62
Apr 261.57
Apr 261.67
Apr 261.69
Mar 261.72
Mar 261.59
Mar 261.54
Mar 261.62
Feb 261.4
Feb 261.41
Feb 261.36
Feb 261.32
Jan 261.28
Jan 261.17
Jan 261.14
Jan 261.09
Jan 261.11
Dec 251.05
Dec 251.04
Dec 251.15
Dec 251.14
Nov 251.14
Nov 251.1
Nov 251.16
Nov 251.1
Oct 251.15
Oct 251.16
Oct 251.15
Oct 251.19
Oct 251.29
Sep 251.38
Sep 251.34
Sep 251.29
Sep 251.2
Aug 251.21
Aug 251.22
Aug 251.18
Aug 251.16
Aug 251.27
Jul 251.34
Jul 251.39
Jul 251.3
Jul 251.28
Jun 251.24
Jun 251.27
Jun 251.28
Jun 251.21
May 251.2
May 251.14
May 251.16
May 251.1
May 251.11
Apr 251.09
Apr 251.1
Apr 251.05
Apr 251.07
Mar 251.35
Mar 251.34
Mar 251.34
Mar 251.27
Feb 251.51
Feb 251.6
Feb 251.63
Feb 251.59
Jan 251.67
Jan 251.78
Jan 251.82
Jan 251.79
Jan 251.76
Dec 241.7
Dec 241.71
Dec 241.86
Dec 241.82
Nov 242
Nov 242.02
Nov 241.92
Nov 241.93
Nov 241.53
Oct 241.55
EV/EBITDA
0510152025med 4.47Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
CRC EV/EBITDA by year
PeriodEV/EBITDA
Sep 2612.32
Sep 2612.49
Sep 2612.04
Aug 2611.69
Aug 2611.87
Aug 2611.88
Aug 2619.03
Jul 2619.19
Jul 2619.43
Jul 2619.25
Jul 2619.14
Jul 2618.8
Jun 2619.5
Jun 2619.95
Jun 2620.88
Jun 2620.81
May 2621.08
May 2621.86
May 2621.6
May 2620.97
May 265.82
Apr 265.56
Apr 265.42
Apr 265.69
Apr 265.77
Mar 265.85
Mar 265.48
Mar 265.33
Mar 265.56
Feb 264.63
Feb 264.66
Feb 264.5
Feb 264.4
Jan 264.28
Jan 263.98
Jan 263.91
Jan 263.75
Jan 263.8
Dec 253.65
Dec 253.62
Dec 253.93
Dec 253.89
Nov 253.9
Nov 253.79
Nov 253.97
Nov 253.79
Oct 253.07
Oct 253.1
Oct 253.08
Oct 253.16
Oct 253.37
Sep 253.56
Sep 253.49
Sep 253.38
Sep 253.17
Aug 253.21
Aug 253.22
Aug 253.13
Aug 253.09
Aug 253.75
Jul 253.92
Jul 254.04
Jul 253.81
Jul 253.77
Jun 253.67
Jun 253.73
Jun 253.78
Jun 253.6
May 253.57
May 253.43
May 253.47
May 253.33
May 253.84
Apr 253.79
Apr 253.79
Apr 253.68
Apr 253.72
Mar 254.48
Mar 254.48
Mar 254.46
Mar 254.28
Feb 254.2
Feb 254.41
Feb 254.48
Feb 254.38
Jan 254.55
Jan 254.8
Jan 254.89
Jan 254.82
Jan 254.76
Dec 244.63
Dec 244.65
Dec 244.98
Dec 244.88
Nov 245.3
Nov 245.34
Nov 245.11
Nov 245.14
Nov 246.78
Oct 246.84
Price/Operating Cashflow
4681012med 5.99Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
CRC Price/Operating Cashflow by year
PeriodPrice/Operating Cashflow
Sep 265.59
Sep 265.69
Sep 265.43
Aug 265.23
Aug 265.34
Aug 265.34
Aug 265.86
Jul 265.92
Jul 266.02
Jul 265.95
Jul 265.91
Jul 265.77
Jun 266.05
Jun 266.22
Jun 266.6
Jun 266.57
May 266.67
May 266.98
May 266.88
May 266.63
May 266.88
Apr 266.51
Apr 266.31
Apr 266.69
Apr 266.81
Mar 266.93
Mar 266.39
Mar 266.18
Mar 266.51
Feb 265.93
Feb 265.97
Feb 265.74
Feb 265.59
Jan 265.4
Jan 264.95
Jan 264.83
Jan 264.59
Jan 264.68
Dec 254.44
Dec 254.4
Dec 254.87
Dec 254.8
Nov 254.82
Nov 254.66
Nov 254.92
Nov 254.66
Oct 255.4
Oct 255.45
Oct 255.42
Oct 255.58
Oct 256.05
Sep 256.46
Sep 256.3
Sep 256.07
Sep 255.62
Aug 255.69
Aug 255.72
Aug 255.52
Aug 255.45
Aug 255.96
Jul 256.29
Jul 256.52
Jul 256.09
Jul 256
Jun 255.81
Jun 255.93
Jun 256.01
Jun 255.68
May 255.62
May 255.36
May 255.42
May 255.16
May 255.44
Apr 255.35
Apr 255.35
Apr 255.15
Apr 255.23
Mar 256.58
Mar 256.57
Mar 256.54
Mar 256.23
Feb 257.64
Feb 258.11
Feb 258.26
Feb 258.04
Jan 258.43
Jan 258.99
Jan 259.18
Jan 259.03
Jan 258.9
Dec 248.6
Dec 248.66
Dec 249.41
Dec 249.18
Nov 2410.13
Nov 2410.21
Nov 249.69
Nov 249.75
Nov 248.71
Oct 248.8
Price to Book
0.511.52med 1.31Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
CRC Price to Book by year
PeriodPrice to Book
Sep 261.46
Sep 261.48
Sep 261.42
Aug 261.36
Aug 261.39
Aug 261.39
Aug 261.58
Jul 261.6
Jul 261.63
Jul 261.61
Jul 261.59
Jul 261.56
Jun 261.63
Jun 261.68
Jun 261.78
Jun 261.77
May 261.8
May 261.89
May 261.86
May 261.79
May 261.62
Apr 261.53
Apr 261.49
Apr 261.58
Apr 261.6
Mar 261.63
Mar 261.51
Mar 261.46
Mar 261.53
Feb 261.44
Feb 261.45
Feb 261.39
Feb 261.36
Jan 261.31
Jan 261.2
Jan 261.17
Jan 261.11
Jan 261.13
Dec 251.08
Dec 251.07
Dec 251.18
Dec 251.17
Nov 251.17
Nov 251.13
Nov 251.19
Nov 251.13
Oct 251.23
Oct 251.24
Oct 251.24
Oct 251.27
Oct 251.38
Sep 251.47
Sep 251.44
Sep 251.38
Sep 251.28
Aug 251.3
Aug 251.3
Aug 251.26
Aug 251.24
Aug 251.21
Jul 251.27
Jul 251.32
Jul 251.23
Jul 251.22
Jun 251.18
Jun 251.2
Jun 251.22
Jun 251.15
May 251.14
May 251.08
May 251.1
May 251.05
May 250.93
Apr 250.91
Apr 250.92
Apr 250.88
Apr 250.89
Mar 251.12
Mar 251.12
Mar 251.12
Mar 251.06
Feb 251.14
Feb 251.21
Feb 251.23
Feb 251.2
Jan 251.26
Jan 251.34
Jan 251.37
Jan 251.35
Jan 251.33
Dec 241.28
Dec 241.29
Dec 241.4
Dec 241.37
Nov 241.51
Nov 241.52
Nov 241.44
Nov 241.45
Nov 241.72
Oct 241.74
California Resources Corp
CRC
Stockpicker

Video analysis: CRC

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CRC

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

gurufocus.com · 13 Sep 2026

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/url] that updated data, including overall survival (OS), from

Why Is California Resources (CRC) Up 2.7% Since Last Earnings Report?

zacks.com · 9 Sep 2026

Why Is California Resources (CRC) Up 2.7% Since Last Earnings Report?

California Resources (CRC) reported earnings 30 days ago. What's next for the stock?

California Resources Completes $63M Acquisition of Crimson Midstream

zacks.com · 2 Sep 2026

California Resources Completes $63M Acquisition of Crimson Midstream

CRC's $63 million Crimson acquisition expands its California pipeline network, boosting transport flexibility while opening potential CO2 infrastructure options.

California Resources Corporation Completes Acquisition of Crimson

globenewswire.com · 1 Sep 2026

California Resources Corporation Completes Acquisition of Crimson

LONG BEACH, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) today announced the closing of its approximately $63 million all-cash acquisition of Crimson Midstream Holdings, LLC (“Crimson”) from CorEnergy Infrastructure Trust, Inc. The transaction was approved by the California Public Utilities Commission on August 13, 2026.

Driving California's Energy Future: California Resources Corporation Releases 2025 Sustainability Update

globenewswire.com · 31 Aug 2026

Driving California's Energy Future: California Resources Corporation Releases 2025 Sustainability Update

LONG BEACH, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) today announced the publication of its 2025 Sustainability Report Update and 2025 Sustainability Report Summary. The reports highlight CRC's continued progress in responsibly producing energy, expanding Carbon TerraVault's (CTV) carbon management platform and advancing innovative solutions that support California's evolving energy needs.

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

gurufocus.com · 25 Aug 2026

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lanc

CRC Down 14.1% in 3 Months: Can Cost Gains Turn It Around?

zacks.com · 19 Aug 2026

CRC Down 14.1% in 3 Months: Can Cost Gains Turn It Around?

California Resources is cutting costs and improving drilling efficiency, but weaker estimates and market-access uncertainty continue to weigh on shares.

Is CRC Stock Worth Buying Despite Its Premium Valuation?

zacks.com · 19 Aug 2026

Is CRC Stock Worth Buying Despite Its Premium Valuation?

California Resources Corporation is cutting costs and improving well productivity, but a rich valuation and falling 2026 estimates keep the investment case mixed.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.